Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027

Caribou Biosciences, Inc.

2025-Q1 EPS reported -$0.43 revenue$2,353,000

Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).
Net loss $40.0M vs $41.2M YoY; R&D expenses $35.5M (up from $33.8M) and G&A $9.7M (down from $14.6M).
Discontinued CB-010 lupus trial, CB-012 AML trial, and preclinical work; workforce reduced ~32% with $2.5–3.5M cash costs.
CB-010 (2L LBCL) and CB-011 (multiple myeloma) Phase 1 data expected in H2 2025 with FDA interaction for potential pivotal trial.
Licensing revenue flat at $2.4M for the quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.